We are live on ! Find out more
FLGT icon

Fulgent Genetics

158 hedge funds and large institutions have $278M invested in Fulgent Genetics in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 49 increasing their positions, 55 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $405K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.83% less ownership

Funds ownership: 57.75%55.92% (-1.8%)

11% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 55

12% less funds holding

Funds holding: 179158 (-21)

37% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 46

41% less capital invested

Capital invested by funds: $469M → $278M (-$191M)

Holders
158
Holders Change
-21
Holders Change %
-11.73%
% of All Funds
1.93%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
29
Increased
49
Reduced
55
Closed
46
Calls
$1.57M
Puts
$405K
Net Calls
+$1.17M
Net Calls Change
-$4.28M

FLGT Hedge Fund Activity: Q1 2026 in Review

158 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q1 2026, worth a combined $278M — down 41% from $469M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of FLGT and 29 opened new positions — a net loss of 17 holders — while 55 trimmed existing stakes and 49 added.

The largest buyer was Invenomic Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Millennium Management, cutting an estimated $11.7M.

  • 158 institutional investors held Fulgent Genetics (FLGT) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $278M of Fulgent Genetics stock for Q1 2026, down 41% quarter-over-quarter.
  • 29 funds opened new Fulgent Genetics positions in Q1 2026 and 46 closed out, a net change of -17 holders.
  • The largest Fulgent Genetics buyer in Q1 2026 was Invenomic Capital Management, an estimated $13.2M added.
  • The largest Fulgent Genetics seller in Q1 2026 was Millennium Management, an estimated $11.7M sold.

Based on aggregated 13F filings for Q1 2026.